Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights Senti Biosciences, Inc. (Nasdaq: SNTI) today reported operational updates and financial results for the first quarter of 2024.

Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML) Senti Bio today announced the publication of preclinical data that supports the design of the Phase 1 clinical trial of SENTI-202.

Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights – IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second quarter of 2024 – – Cash and anticipated...